Cancer cachexia, recent advances, and future directions

Cancer Journal (United States)

Volumn 21, Issue 2, 2015, Pages 117-122

  Penet, Marie France ^a,b   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer cachexia; molecular mechanisms; noninvasive imaging; treatment options

Indexed keywords

CACHEXIA; CLINICAL ASSESSMENT; HUMAN; INVESTIGATIVE PROCEDURES; MOLECULAR IMAGING; MUSCLE ATROPHY; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; ANIMAL; COMPLICATION; DIAGNOSTIC IMAGING; ENERGY METABOLISM; METABOLISM; NEOPLASMS;

ANIMALS; CACHEXIA; DIAGNOSTIC IMAGING; ENERGY METABOLISM; HUMANS; NEOPLASMS;

EID: 84926669346     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000100     Document Type: Review

References (34)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
2. TisdaleMJ. Cancer cachexia. Langenbecks Arch Surg. 2004;389:299-305.
3. TisdaleMJ, Dhesi JK. Inhibition ofweight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res. 1990;50:5022-5026.
4. Loberg RD, Bradley DA, Tomlins SA, et al. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin. 2007;57:225-241.
5. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89: 381-410.
6. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90-99.
7. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153-166.
8. Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68:234-239.
9. Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014;20:433-447.
10. Bauwens M,Wierts R, van Royen B, et al.Molecular imaging of brown adipose tissue in health and disease. Eur J Nucl Med Mol Imaging. 2014;41: 776-791.
11. Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513: 100-104.
12. Roberts EW, Deonarine A, Jones JO, et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210:1137-1151.
13. GilabertM, Calvo E, Airoldi A, et al. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J Cell Physiol. 2014;229:1437-1443.
14. DiGirolamo FG, Situlin R,Mazzucco S, et al.Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;17:145-150.
15. Molfino A, Formiconi A, Rossi Fanelli F, et al. Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care. 2014;17:471-476.
16. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebocontrolled trial. J Clin Endocrinol Metab. 2004;89:2832-2836.
17. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelinmimetic, in patientswith cancer-related cachexia: amulticenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 2013;21:129-137.
18. Porporato PE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest. 2013;123: 611-622.
19. Molfino A, Gioia G, Muscaritoli M. The hunger hormone ghrelin in cachexia. Expert Opin Biol Ther. 2013;13:465-468.
20. Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329-337.
21. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142:531-543.
22. Muscaritoli M, Molfino A, Gioia G, et al. The "parallel pathway": a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med. 2011;6:105-112.
23. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973-6979.
24. PradoCM, Baracos VE,McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15:2920-2926.
25. del Fabbro E. More is better: a multimodality approach to cancer cachexia. Oncologist. 2010;15:119-121.
26. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-635.
27. Lieffers JR, MourtzakisM,HallKD, et al. Aviscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr. 2009; 89:1173-1179.
28. Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010; 28:1054-1060.
29. Fogelman DR, Holmes H, Mohammed K, et al. Does IGFR1 inhibition result in increasedmusclemass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014;5:307-313.
30. Gray C,MacGillivray TJ, Eeley C, et al. Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin Nutr. 2011;30:106-111.
31. Weber MA, Krakowski-Roosen H, Schroder L, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 2009;48:116-124.
32. Greig CA, Johns N, Gray C, et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer. 2014;22:1269-1275.
33. Penet MF, Gadiya MM, Krishnamachary B, et al. Metabolic signatures imaged in cancer-induced cachexia. Cancer Res. 2011;71: 6948-6956.
34. Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol. 1986;111:82-85.